SAN FRANCISCO, Dec.15, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT.
Conference Call
The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.
the event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following
Nektar Therapeutics to Host Conference Call to Discuss Rezolve AA Phase 2b Study Results
SAN CARLOS, Calif. – December 16, 2025 – Nektar Therapeutics (Nasdaq: NKTR) announced it will hold a conference call to discuss topline results from the 36-week induction treatment period for its Rezolve AA Phase 2b study of rezpegaldesleukin in alopecia areata. The call is scheduled for December 16, 2025.
The Rezolve AA study is evaluating rezpegaldesleukin,an IL-2 pathway agonist,as a potential treatment for severe alopecia areata,an autoimmune disease causing hair loss. https://www.nektar.com/pipeline/rezolve-aa/
Conference Call Details:
Details regarding the time and access facts for the conference call were not provided in the source document. Investors and interested parties are encouraged to visit Nektar’s website at https://www.nektar.com for further details.
Investor & Media Contacts:
* For Investors:
* Vivian wu, 628-895-0661
* Corey Davis, Ph.D., LifeSci Advisors, LLC, cdavis@lifesciadvisors.com, 212-915-2577
* Ahu Demir, Ph.D., LifeSci Advisors, LLC, ademir@lifesciadvisors.com, 212-915-3820
* For Media:
* Jonathan Pappas, LifeSci Communications, 857-205-4403, jpappas@lifescicomms.com
About Nektar Therapeutics:
Nektar Therapeutics is a biopharmaceutical company developing immunotherapeutic agents. https://www.nektar.com Follow Nektar on LinkedIn.
Original Source:
Related reading